News Sentiment

CSTL sentiment intelligence

Castle Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 42 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Diagnostics & Research Read-through group
Latest close 24.16 Week of 17 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

80/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+1.9% over one week, +14.4% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Form 4 Castle Biosciences Inc For: 16 July By Investing.com

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 80/100 classification
One-week reaction 1.9% Price digesting
Trend fit Trend inactive 14.4% over four weeks
Fair value 0.9% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 23
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
Market source 7
Investing.com 5
TradingView 4
Investing.com Nigeria 3
PR Newswire 3
GuruFocus 2
Stock Traders Daily 2

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 9
Analyst action 4
Regulatory and legal 3
Macro sensitivity 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 42
Stock Titan Direct company coverage

Castle Biosciences (CSTL) CEO sells 4,172 shares via family trusts

Castle Biosciences Inc. President and CEO Derek J. Maetzold reported selling 4,172 shares of common stock at a weighted-average price of $22.92 per share on July 14, 2026. These sales were largely executed through family trusts under a pre-arranged Rule 10b5-1 trading plan adopte

Tone
Negative 40/100
Event
Market update
Published
16 Jul 2026 20:42
Source
Stock Titan
Investing.com Direct company coverage

Castle Biosciences receives New York approval for atopic dermatitis test

Castle Biosciences (NASDAQ:CSTL) has received New York State Department of Health approval for its AdvanceAD-Tx test, a non-invasive gene expression profile designed to guide systemic therapy selection for moderate-to-severe atopic dermatitis patients. The company's shares are cu

Tone
Positive 65/100
Event
Regulatory and legal
Published
15 Jul 2026 16:10
Source
Investing.com
Investing.com Nigeria Direct company coverage

Castle Biosciences receives New York approval for atopic dermatitis test By Investing.com

Castle Biosciences (NASDAQ: CSTL) has received approval from the New York State Department of Health for its AdvanceAD-Tx test, a non-invasive gene expression profile designed to guide systemic therapy selection for moderate-to-severe atopic dermatitis patients. The company's sha

Tone
Positive 71/100
Event
Regulatory and legal
Published
15 Jul 2026 03:42
Source
Investing.com Nigeria
PR Newswire Direct company coverage

Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test

Castle Biosciences has received New York State Department of Health approval for its AdvanceAD-Tx test, a non-invasive gene expression profile test designed to guide systemic treatment decisions for patients with moderate-to-severe atopic dermatitis. This approval expands access

Tone
Positive 74/100
Event
Regulatory and legal
Published
14 Jul 2026 20:16
Source
PR Newswire
GuruFocus Direct company coverage

Castle Biosciences (CSTL) to Release Q2 Financial Results on Jul

Castle Biosciences (CSTL) announced it will release its Q2 2026 financial results on July 30, 2026, after market close, followed by a webcast. GuruFocus assesses CSTL as 19.0% undervalued with a GF Value™ of $29.19 and a strong GF Score™ of 77/100, driven by excellent financial s

Tone
Positive 66/100
Event
Earnings
Published
09 Jul 2026 14:13
Source
GuruFocus
Market source Direct company coverage

Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026

Castle Biosciences, Inc. (Nasdaq: CSTL) announced it will release its second-quarter 2026 financial results after market close on Thursday, July 30, 2026. Following the release, company management will host a webcast at 4:30 p.m. Eastern time to discuss the results and conduct a

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 11:13
Source
Market source
Stock Titan Direct company coverage

Castle Biosciences sets July 30 webcast for Q2 results

Castle Biosciences (Nasdaq: CSTL) will release its second-quarter 2026 financial results after market close on Thursday, July 30, 2026. The company will host a webcast at 4:30 p.m. Eastern time to discuss these results, followed by a Q&A session. A prior earnings-date notice resu

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 10:42
Source
Stock Titan
AD HOC NEWS Direct company coverage

Castle Biosciences updates its melanoma testing strategy as diagnostics demand grows

Castle Biosciences is refining its melanoma testing strategy to meet the increasing demand for precise diagnostic tools in cancer. The company specializes in molecular diagnostics for skin cancers and solid tumors, focusing on tests that assess the risk of melanoma recurrence or

Tone
Positive 76/100
Event
Macro sensitivity
Published
08 Jul 2026 17:40
Source
AD HOC NEWS
Investing.com Nigeria Direct company coverage

Form 4 Castle Biosciences Inc For: 6 July By Investing.com

This article reports on a Form 4 filing for Castle Biosciences Inc. on July 6. The content is primarily a placeholder or metadata posting rather than a detailed news report, indicated by the repetitive title and a lack of specific financial details beyond general market data. It

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 21:32
Source
Investing.com Nigeria
Investing.com Direct company coverage

Derek Maetzold, pres. & CEO, sells $238,916 of Castle Biosciences stock

Derek Maetzold, President and CEO of Castle Biosciences Inc. (NASDAQ: CSTL), sold 9,834 shares of company stock for approximately $238,916 through direct and indirect trusts, as reported in an SEC filing. Concurrently, he acquired 6,214 shares by exercising stock options as part

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 20:41
Source
Investing.com
Stock Titan Direct company coverage

Castle Biosciences (CSTL) CEO sells 9,836 shares via 10b5-1 plan

Castle Biosciences CEO Derek Maetzold, through associated entities, sold 9,836 shares of common stock at a weighted-average price of $24.29 per share on July 1, 2026, pursuant to a pre-arranged Rule 10b5-1 plan. Concurrently, he exercised options for 6,214 shares at $2.39 each. T

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 20:41
Source
Stock Titan
Stock Titan Direct company coverage

Castle Biosciences (CSTL) COO sells 8,586 shares under 10b5-1 plan

Castle Biosciences' Chief Operating Officer, Kristen M. Oelschlager, sold a total of 8,586 shares of Common Stock on July 1, 2026, through a pre-arranged Rule 10b5-1 trading plan. The shares were sold in two weighted-average price transactions at $24.40 and $24.78 per share. Foll

Tone
Negative 30/100
Event
Market update
Published
06 Jul 2026 20:41
Source
Stock Titan
Stock Traders Daily Direct company coverage

The Technical Signals Behind (CSTL) That Institutions Follow

This article analyzes Castle Biosciences Inc. (NASDAQ: CSTL), highlighting strong sentiment across all time horizons supporting an overweight bias. It details several AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and st

Tone
Positive 66/100
Event
Analyst action
Published
06 Jul 2026 16:10
Source
Stock Traders Daily
TradingView Direct company coverage

Enterprise value to revenue forward of Castle Biosciences, Inc. – NASDAQ:CSTL

The article focuses on the enterprise value to forward revenue of Castle Biosciences, Inc. (NASDAQ: CSTL). It appears to be a financial data point presented within the context of TradingView's platform, indicating analytical information for investors and traders.

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 12:10
Source
TradingView
Investing.com Canada Direct company coverage

Form 144 Castle Biosciences For: 1 July By Investing.com

This article announces the filing of Form 144 for Castle Biosciences (CSTL) on July 1st. It also includes current stock market data and various financial news headlines from Investing.com. The company's stock symbol is CSTL, and it shows a 3.61% increase.

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 22:09
Source
Investing.com Canada
Stock Titan Direct company coverage

Maetzold family Rule 144 sales reported for CSTL (CSTL) — multiple small lots

Multiple Rule 144 sale notices by Derek Maetzold and related trusts regarding CASTLE BIOSCIENCES INC (CSTL) have been reported, listing numerous small open-market dispositions of Common shares between April and June 2026. The sales, which include those from trusts like The Maetzo

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 21:09
Source
Stock Titan
Stock Traders Daily Direct company coverage

Precision Trading with Castle Biosciences Inc. (CSTL) Risk Zones

This article provides a precision trading analysis for Castle Biosciences Inc. (CSTL) as of June 25, 2026, highlighting a strong near-term sentiment with a long-term positive bias. It details an exceptional risk-reward setup targeting a 46.0% gain versus a 0.3% risk, along with s

Tone
Positive 72/100
Event
Market update
Published
27 Jun 2026 11:40
Source
Stock Traders Daily
TradingView Direct company coverage

Castle Biosciences, Inc. Actuals & Estimates (TRADEGATE:086)

This article provides an overview of Castle Biosciences, Inc. (TRADEGATE:086) financial actuals and estimates, including income statement, balance sheet, and cash flow data, as well as analyst price targets. It also includes frequently asked questions regarding the company's stoc

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 21:39
Source
TradingView
TradingView Direct company coverage

Castle Biosciences, Inc. Actuals & Estimates (NASDAQ:CSTL)

This article provides an overview of Castle Biosciences, Inc. (NASDAQ:CSTL) stock performance, financial estimates, and analyst forecasts. It covers current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings dates, along with insights

Tone
Positive 67/100
Event
Earnings
Published
26 Jun 2026 06:11
Source
TradingView
Market source Direct company coverage

Castle Biosciences (CSTL) Stock Sees Split Analyst Revisions As Price Targets Come Down

Analyst price targets for Castle Biosciences (CSTL) have seen mixed revisions, with some targets lowered from the US$50 range to the mid-US$30s and US$40s, reflecting a more cautious outlook on growth and profitability. While some analysts maintain a "Buy" rating, citing strong r

Tone
Negative 37/100
Event
Analyst action
Published
26 Jun 2026 06:07
Source
Market source
Nasdaq Direct company coverage

Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal

Castle Biosciences' Chief Financial Officer, Frank Stokes, has been recognized as a 2026 CFO Awards honoree by the Houston Business Journal. This award acknowledges his financial leadership and contributions, including guiding the company through its Nasdaq IPO and multiple strat

Tone
Positive 70/100
Event
Market update
Published
25 Jun 2026 23:10
Source
Nasdaq
Investing.com Direct company coverage

Castle Biosciences’ melanoma test outperforms risk tool

Castle Biosciences (NASDAQ:CSTL) announced that its DecisionDx-Melanoma i31-SLNB test significantly outperformed the Melanoma Institute Australia nomogram in identifying low and high-risk melanoma patients, as published in Dermatology and Therapy. The company, with a strong gross

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 21:11
Source
Investing.com
Moomoo Direct company coverage

Roth Capital Initiates Castle Biosciences at Buy

Roth Capital has initiated coverage on Castle Biosciences with a "Buy" rating. This indicates a positive outlook from the investment firm regarding the company's stock. Investors will be watching for further details on the rationale behind this rating.

Tone
Positive 76/100
Event
Guidance
Published
25 Jun 2026 20:11
Source
Moomoo
Stock Titan Direct company coverage

Castle Biosciences test better spots melanoma patients who may skip surgery

Castle Biosciences announced that its DecisionDx-Melanoma i31-SLNB test significantly outperformed the MIA nomogram in a prospective, multicenter study for identifying cutaneous melanoma patients who could safely avoid sentinel lymph node biopsy (SLNB). The i31-SLNB test accurate

Tone
Positive 76/100
Event
Market update
Published
25 Jun 2026 20:11
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBIT forward of Castle Biosciences, Inc. – NASDAQ:CSTL

This article focuses on the "Enterprise value to EBIT forward" metric for Castle Biosciences, Inc. (NASDAQ: CSTL) as listed on TradingView. It appears to be a financial data snippet rather than a comprehensive article, indicating a reporting of this specific financial ratio for t

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 20:11
Source
TradingView